COPD and perception of the new GOLD document in Europe. Workshop from the société de pneumologie de langue Française (SPLF);La BPCO et la perception du nouveau document GOLD en Europe. Workshop de la société de pneumologie de langue Française (SPLF)

Revue des Maladies Respiratoires

Volumn 31, Issue 6, 2014, Pages 499-510

  Zysman, M ^a   Patout, M ^b   Miravitlles, M ^c   Van Der Molen, T ^d   Lokke, A ^e   Hausen, T ^f   Didier, A ^g   Cuvelier, A ^b   Roche, N ^h  

^a CHU NANCY BRABOIS   (France)

^b University of Rouen   (France)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f General Practice Surgery   (Belgium)

^g SERVICE DE PNEUMOLOGIE   (France)

^h université Paris Cité   (France)

Author keywords

Chronic obstructivepulmonary disease; Epidemiology; Screening; Tobacco smoking; Treatment

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVELOPED COUNTRY; EDUCATION; HUMAN; MORTALITY; OCCUPATIONAL HAZARD; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; SMOKING; SMOKING CESSATION; WORKSHOP; CAUSE OF DEATH; DEATH CERTIFICATE; EPIDEMIOLOGICAL DATA; FRANCE; GENERAL PRACTICE; MASS SCREENING; PREVALENCE; REIMBURSEMENT; RISK FACTOR; SPIROMETRY; TOBACCO; AGED; FEMALE; MALE; MIDDLE AGED; ORGANIZATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICS AND NUMERICAL DATA; CONSENSUS; CONSENSUS DEVELOPMENT; EUROPE; EXPERT WITNESS; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PERCEPTION; POLITICS; PRACTICE GUIDELINE; PULMONOLOGY; STANDARDS; TELEMEDICINE;

AGED; CONGRESSES AS TOPIC; EDUCATION; FEMALE; FRANCE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; CONSENSUS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; EUROPE; EXPERT TESTIMONY; PERCEPTION; POLITICS; PRACTICE GUIDELINES AS TOPIC; PULMONARY MEDICINE; SOCIETIES, MEDICAL; TELEMEDICINE;

EID: 84922830334     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2014.02.014     Document Type: Review

References (47)

1. Cerveri I, Accordini S, Verlato G, et al. Variations in the preva-lence across countries of chronic bronchitis and smoking habitsin young adults. Eur Respir J 2001;18:85-92.
2. Pena VS, Miravitlles M, Gabrile R, et al. Geographic variations inprevalence and underdiagnosis of COPD. Results of the Iberpocmulticentre epidemiological study. Chest 2000;118:981-9.
3. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of lifeand daily life activities. Thorax 2009;64:863-5.
4. Soriano JB, Ancochea J, Miravitlles M, et al. Recent trends inCOPD prevalence in Spain: a repeated cross-sectional survey1997-2007. Eur Respir J 2010;36:758-65.
5. Vasankari TM, Impivaara O, Heliovaara M, et al. No increasein the prevalence of COPD in two decades. Eur Respir J 2010;36:766-73.
6. Martinez FJ, Raczec AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population ScreenerQuestionnaire (COPD-PS). COPD 2008;5:85-95.
7. Miravitlles M, Llor C, Calvo E, et al. Validation ofthe Spanish version of the chronic Obstructive PulmonaryDisease-Population Screener (COPD-PS). Its usefulness and that of FEV1/FEV6 for the diagnosis in COPD. Med Clin 2012;139:522-30.
8. Soler-Cataluña, Calle M, Cosio BG, et al. Health-care quality standards in chronic obstructive pulmonary disease. Arch Bron-coneumol 2009;45:196-203.
9. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pul-monary disease phenotypes: the future of COPD. Am J RespirCrit Care Med 2010;182:598-604.
10. Miravitlles M, Soler-Cataluña, Calle M, et al. Spanish COPD gui-delines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012;48:247-57.
11. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-35.
12. Miravitlles M, Soriano JB, Ancochea J, et al. Characterization ofthe overlap COPD asthma phenotype. Focus on physical activityand health status. Resp Med 2013;107:1053-60.
13. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: pre-dicting from high-dose inhaled corticosteroid treatment. EurRespir J 2006;27:964-71.
14. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility ofairflow limitation and increased exhaled NO and sputum eosi-nophilia in chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2000;162:1773-7.
15. Magnussen H, Bugnas B, van Noord J, et al. Improvements withtiotropium in COPD patients with concomitant asthma. RespirMed 2008;102:50-6.
16. Siva R, Green RH, Brightling CE, et al. Eosinophilic air-way inflammation and exacerbations of COPD: a randomisedcontrolled trial. Eur Respir J 2007;29:906-13.
17. Rennard SI, Calverley PM, Goehring UM, et al. Reduction ofexacerbations by IPDE4 inhibitro roflumilast: the importanceof defining different subsets of patients with COPD. Respir Res 2011;12:18.
18. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for theprevention of exacerbations of chronic obstructive pulmonarydisease: a randomized controlled trial. Respir Res 2010;11:10.
19. Miravittles M, Soler-Cataluna JJ, Calle M, et al. A new approachto grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim CareRespir J 2013;22:117-21.
20. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Treatment of COPD by clinical phenotypes. Putting old evidence into clinicalpractice. Eur Respir J 2013;41:1.
21. Bolibar B, Fina Avies F, Morros R, et al. SIDIAP database: electro-nic clinical records in primary care as a source of informationfor epidemiologic research. Med Clin 2012;138:617-21.
22. Bourdin A, Serre I, Flamme H, et al. Can endobronchial biopsyanalysis be recommended to discriminate between asthma and COPD in routine practice? Thorax 2004;59:488-93.
23. Calverley PM, Burge PS, Spencer S, et al. Bronchodilatatorreversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64.
24. Partridge MR, van der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
25. Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasibility and accessibility of training by pharmacists. RespirMed 2011;105:1815-22.
26. Løkke A, Fabricius PG, Vestbo J, et al. Prevalence of chro-nic obstructive pulmonary disease in Copenhagen. Resultsfrom The Copenhagen City Heart Study. UfL 2007;169:3956-60.
27. Ulrik CS, Hansen EF, Jensen MS, et al. Management of COPDin general practice in Denmark: participating in educationalprogram substantially improves adherence to guidelines. InternJ COPD 2010;5:73-9.
28. Ulrik CS, Sorensen TB, Hojmark TB, et al. Adherence to COPDguidelines in general practice: impact of an educational pro-gramme delivered on location in Danish general practice. PrimCare Resp J 2013;22:23-8.
29. Ulrik CS, Lokke A, Dahl R, et al. Early detection of COPD ingeneral practice. Int J COPD 2011;6:123-7.
30. Lokke A, Ulrik CS, Dahi R, et al. Detection of previously undiag-nosed cases of COPD in a high-risk population indentified ingeneral practice. COPD 2012;9:458-65.
31. Løkke A, Dahl R. [New guidelines for diagnosis and stagingof chronic obstructive pulmonary disease]. Ugeskr Laeger 2013;175:1257-60.
32. Hausen T. Staged therapy of chronic obstructive respiratorytract disease: treatments of chronic obstructive respiratorytract diseases by the established physician. MMW Fortschr Med 1989;107:210-3.
33. Hausen T. Value of spirometry in the early diagnosis of respira-tory system disease. Dtsch Med Wschr 1985;110:59-63.
34. Müller M, Kogler H, Glaab T, et al. Use of lung function scree-ning device for identifying patients at risk for COPD in generalpractice. Pneumologie 2012;66:645-9.
35. Global initiative for chronic obstructive lung disease. Globalstrategy for the diagnosis, management and prevention of chronic obstructive lung disease; 2011 [http://goldcopd.com].
36. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health rela-ted quality of life and mortality in male patients with chronicobstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680-5.
37. Spencer S, Calverley PM, Burge PS, et al. Impact of preventingexacerbations on deterioration of health status in COPD. EurRespir J 2004;23:698-702.
38. Jones PW, Quirk FH, Baveystock CM, et al. A self-completemeasure of health status for chronic airflow limitation. TheSaint-George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
39. Jones PW. Health status measurement in chronic obstructivepulmonary disease. Thorax 2001;56:880-7.
40. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54.
41. Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. EurRespir J 2011;38:29-35.
42. Marchand E, Maury G. Evaluation du COPD Assessment Test (CAT) chez les patients BPCO en état stable. Rev Mal Respir 2012;29:391-7.
43. Van der Molen T, Willemse BW, Schokker S, et al. Development validity and responsiveness of the clinicalCOPD Questionnaire. Health Qual Life Outcomes 2003;1:1-13.
44. Sin DD, Anthonisen NR, Soriano JB, et al. Mortalityin COPD: role of comorbidities. Eur Respir J 2006;28:1245-57.
45. HAS. Bon usage du médicament. Quelle place sur les broncho-dilatateurs de longue d'action dans le traitement de la BPCO ?; 2009 [http://has-sante.fr/portail/upload/docs/application/pdf/ficheBUMBPCO210408.pdf] .
46. Roche N. Position de la Société de pneumologie en languefrançaise vis-à-vis de la version 2011 des recommandationsGOLD. Rev Mal Respir 2012;29:637-9.
47. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish Guide-lines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. ArchBronconeumol 2012;48:247-57.